135716-09-5

Basic information

• Product Name: N-BOC-4-ETHYL PIPERIDINECARBOXYLATE
• Synonyms: N-BOC-4-ETHYL PIPERIDINECARBOXYLATE;tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate(SALTDATA: FREE);Ethyl N-Boc-4-piperidineacetate;Ethyl 1-Boc-4-piperidine ...;Ethyl 1-Boc-4-piperidine acetate;1-[(tert-butoxy)carbonyl]-4-ethylpiperidine-2-carboxylate;tert-Butyl 4-(2-ethoxy-2-oxoethyl)piperidin-1-carboxylate;4-Piperidineacetic acid, 1-[(1,1-diMethylethoxy)carbonyl]-, ethyl ester
• CAS NO: 135716-09-5
• Molecular Formula: C₁₄H₂₅NO₄
• Molecular Weight: 271.35
• Mol File: 135716-09-5.mol
• Article Data: 34

Chemical Properties

• Boiling Point: 339.2±15.0 °C(Predicted)
• Appearance: /
• Density: 1.048±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1?+-.0.40(Predicted)
• CAS DataBase Reference: N-BOC-4-ETHYL PIPERIDINECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-4-ETHYL PIPERIDINECARBOXYLATE(135716-09-5)
• EPA Substance Registry System: N-BOC-4-ETHYL PIPERIDINECARBOXYLATE(135716-09-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 135716-09-5(Hazardous Substances Data)

Usage

General Description

N-BOC-4-ethyl piperidinecarboxylate is a chemical compound used as a building block in organic synthesis. It is a BOC-protected amino acid derivative, with the BOC (tert-butoxycarbonyl) group protecting the amino group. N-BOC-4-ETHYL PIPERIDINECARBOXYLATE is often used in the pharmaceutical industry for the synthesis of various drugs and drug candidates. Its unique structure and reactivity make it a valuable tool for the creation of complex organic molecules, and it is also used in research and development of new chemical and pharmaceutical products.

Upstream product

• 135716-08-4 tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 34619-03-9 tert-butyldicarbonate 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 75-03-6 ethyl iodide 
• 157688-46-5 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid 
• 64-17-5 ethanol 
• 135716-12-0 (R)-(+)-2-(N-tert-butoxycarbonylpiperidin-4-yl)-2-(6-chloropyrazin-2-yl)ethanol 
• 59184-90-6 ethyl (piperidin-4-yl)acetate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 41979-39-9 4-piperidone hydrochloride 

Downstream Products

• 142374-19-4 tert-butyl 4-(formylmethyl)piperidine-1-carboxylate 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 287393-45-7 tert-butyl 4-(1-{[4-(2-butynyloxy)phenyl]sulfonyl}-2-ethoxy-2-oxoethyl)-1-piperidinecarboxylate 
• 146093-46-1 4-(2-aminoethyl)-1-piperidinecarboxylic acid tert-butyl ester 
• 147699-19-2 tert-butyl 4-{2-[(methylsulfonyl)oxy]ethyl}piperidine-1-carboxylate 
• 663170-84-1 (R)-1-[4-(2-Azido-ethyl)-piperidin-1-yl]-2-((R)-3,3-difluoro-cyclopentyl)-2-hydroxy-2-phenyl-ethanone 
• 301185-40-0 1-(t-butoxycarbonyl)-4-(3,3-dibromoprop-2-en-1-yl)piperidine 
• 339525-17-6 1-(o-iodobenzoyl)-4-[3-(trimethylsilyl)prop-2-ynyl]piperidine 
• 339525-21-2 1-(o-iodobenzoyl)-4-[4-(trimethylsilyl)but-3-ynyl]piperidine 
• 157688-46-5 2-(1-(tert-butoxycarbonyl)piperidin-4-yl)acetic acid 
• 59184-90-6 ethyl (piperidin-4-yl)acetate 
• 271577-10-7 1,1-dimethylethyl 4-[2-oxo-3-(4-pyridinyl)propyl]-1-piperidinecarboxylate 
• 183170-69-6 1-tert-Butyloxycarbonyl-4-hydroxyethyl-piperidine 

Relevant articles and documents

Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease

A series of oxadiazole derivatives were synthesized and evaluated as 5-hydroxytryptamine-4 receptor (5-HT4R) partial agonists for the treatment of cognitive deficits associated with Alzheimer's disease. Starting from a reported 5-HT4R antagonist, a systematic structure-activity relationship was conducted, which led to the discovery of potent and selective 5-HT4R partial agonist 1-isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate (Usmarapride, 12l). It showed balanced physicochemical-pharmacokinetic properties with robust nonclinical efficacy in cognition models. It also showed disease-modifying potential, as it increased neuroprotective soluble amyloid precursor protein alpha levels, and dose-dependent target engagement and correlation of efficacy with oral exposures. Phase 1 clinical studies have been completed and projected efficacious concentration was achieved without any major safety concerns. Phase 2 enabling long-term safety studies have been completed with no concerns for further development.

Piperidine amino derivative and application thereof in fighting schizophrenia

The invention discloses a piperidine amino compound and an application thereof in fighting schizophrenia. Pharmacological experiment results show that the piperidine amino compound related to by the invention has good water solubility, has high affinity with dopamine D, D, 5-HT, and 5-HT receptors, and has good selectivity on D/D receptors. In-vivo test results show that a preferable compound has a good anti-schizophrenia effect, is relatively low in acute toxicity, high in safety and good in pharmacokinetic characteristic, and has a development value as a high-efficiency low-toxicity novel anti-schizophrenia new drug. The piperidine amino compounds are compounds represented as a structural general formula (I), or salts of the compounds, or hydrates of the salts.

HETEROAROMATIC ELECTROPHILES AND METHODS OF USING THEREOF

Disclosed herein are compounds, compositions, and methods for reactivating or realkylating aged acetylcholinesterase inhibited by or conjugated to the organophosphorus compound. The organophosphorus compound can be a nerve agent. The acetylcholinesterase can be in the central nerve system (CNS) and/or the peripheral nervous system (PNS) of a subject. Accordingly, methods for ameliorating, diminishing, reversing, treating or preventing the toxic effects of an organophosphorus compound in a subject are provided herein. Methods for prophylactic or therapeutic treatment of exposure to an organophosphorus nerve agent are also provided.